Physician profile
Ramji R Rajendran
NPI 1982760773
$207,465.49
in general payments reported to CMS, 2019-2025
32 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2021: $363 · 2022: $17K · 2023: $74K · 2024: $49K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $79K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Honoraria: $23K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $19K · Travel and Lodging: $13K · Food and Beverage: $7,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $79,469.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,340.00 |
| Honoraria | $22,715.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,450.00 |
| Travel and Lodging | $12,991.70 |
| Food and Beverage | $7,096.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $70,675.70 | 2022-2025 | Optune, Optune Gio, Optune Lua (Novottf-200t) |
| Astrazeneca Pharmaceuticals Lp | $67,499.02 | 2021-2025 | Imfinzi, Tagrisso |
| Davol INC. | $33,000.00 | 2023 | |
| Telix Pharmaceuticals | $26,055.42 | 2024-2025 | Illuccix |
| Novartis Pharmaceuticals Corporation | $5,313.32 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,207.42 | 2019-2025 | |
| Endomagnetics Ltd | $590.58 | 2022-2023 | Magtrace, Magseed |
| Siemens Medical Solutions USA, INC. | $404.49 | 2025 | Varian Ethos Treatment Planning, Truebeam |
| Bioprotect Medical, INC. | $299.28 | 2024-2025 | Bioprotect Balloon Implant System |
| Elekta, INC. | $290.78 | 2024 | Elekta Medical Linear Accelerator, Leksell Gamma Knife Icon |
| Blue Earth Diagnostics | $232.87 | 2021-2025 | Posluma |
| Merck Sharp & Dohme LLC | $213.02 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Research & Development, LLC | $103.66 | 2025 | |
| Accuray Incorporated | $83.35 | 2021 | |
| Myriad Genetic Laboratories, INC. | $79.83 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ablative Solutions, INC. | $76.74 | 2022 | |
| Progenics Pharmaceuticals, INC. | $53.11 | 2025 | |
| Penumbra, INC. | $33.79 | 2021 | |
| Sumitomo Pharma America, INC. | $28.47 | 2024 | Orgovyx |
| Erbe USA INC | $25.97 | 2023 | |
| Reflexion Medical, INC. | $25.00 | 2022 | |
| Daiichi Sankyo INC. | $23.99 | 2022 | |
| Eisai INC. | $23.45 | 2024 | |
| Boston Scientific Corporation | $22.20 | 2024 | Spaceoar Vue System - 10ml |
| Servier Pharmaceuticals LLC | $21.49 | 2025 | |
| Teleflex LLC | $20.52 | 2025 | Barrigel |
| Genentech USA, INC. | $18.51 | 2025 | Itovebi |
| Tolmar, INC. | $15.18 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $15.18 | 2025 | Rubraca |
| Tactile Systems Technology INC | $13.15 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramji Rajendran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.